Director Articles

The need for accurate epidemiology data to drive a higher success rate with Health Technology Assessments

Most drug or device launches today require a health economic valuation often in the form of a Health Technology Assessment (HTA) to satisfy payers that the new ‘technology’ is advantageous for the health system. Most HTAs include epidemiology data in some form. This is often included in order to understand the impact of the technology…

Portfolio Optimisation: Can you really compare Apples to Oranges?

On July 5, 2016, In Director Articles,
When someone uses the expression "you're comparing apples to oranges" they're really saying "Why are you trying to compare those things? You can't compare apples to oranges; they're just not the same thing. On further analysis, you could say, “They're both round. They're both sweet. They're both fruit. They're both the same. But they're not.”…

Forecasting In Forgotten Markets

On April 8, 2016, In Director Articles,
Two recent healthcare events supported by the One Nucleus biotech network, has nicely highlighted some of the challenges facing healthcare companies and investors that are looking to bring innovative solutions to these markets that have had limited historically success and subsequently attracted limited investment. One of these industry events was focused on the recent developments in…

Forecasting in Dynamic Oncology Markets

On March 14, 2016, In Director Articles,
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month. Firstly how exciting the market is right now, with many productive collaborations between academia, biotech’s, big pharma and charities being discussed. Secondly how challenging it will be for health systems to respond to such rapid change, particularly to the…

Shire bets big on rare diseases

On January 19, 2016, In Director Articles, Tags ,,,
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical arm of Baxter, initially rejected Shire’s advances in mid-2015, saying the newly-formed company needed time to decide on its strategy. Shire gets 45% of its revenue…